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Helicases are enzymes involved in all aspects 
of nucleic acid metabolism.1 Because of their 
essential function, helicases are ubiquitous and 
evolutionarily conserved proteins. Helicase s 
are characterized by the presence of con-
served motifs in the form of short amino acid 
sequences. Based on variations of the number 
of motifs, their amino acid sequence and spac-
ing, helicases have been grouped into super-
families (SF), including three large (SF1–SF3) 
and two small (SF4 and SF5) ones.2 The crystal 
structures of several representative helicases 
revealed common features. Monomeric heli-
cases (SF1/SF2) have a core that consists of 
two domains with a linker region. Hexameric 
helicases (SF3-SF5) form a core that includes 
six individual domains arranged in a ring. The 
domains are termed RecA-like because of 
their  similarity to the ATP binding core of 
RecA recombination protein. The conserved 
helicase motifs include those involved in NTP 
binding and hydrolysis, which are similar to the 
Walker A and B boxes of ATPase. The other 
conserved motifs are involved in coupling of the 
NTP hydrolytic state to protein conformational 
changes and in nucleic acid binding.3 
Helicases utilize the energy derived from 
nucleoside triphosphate hydrolysis to translo-
cate along nucleic acid strands, unwind/separate 
the helical structure of double-stranded nucleic 
acid and, in some cases, disrupt protein-nucleic 
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acid interactions.4 Depending on their nucleic 
acid targets, helicases are generally classified 
as DNA or RNA helicases. DNA helicases are 
involved in replication, repair and recombina-
tion. RNA helicases are involved in all aspects 
of RNA metabolism. The majority of RNA heli-
cases belongs to DexD/H-box proteins which 
derive this name from the single letter code of 
the four amino acids of motif ii.5 They are classi-
fied into several subgroups including DeAD-box 
(DDX) and DeAH-box (DHX) families which 
are distinguished by consistent sequence differ-
ences that extend beyond motif ii.6 
in addition to the basic study of their bio-
chemical and biophysical properties, interest in 
helicases includes their potential use as targets 
of novel therapies. An example is the research 
conducted to identify inhibitors of viral RNA 
helicases.7 Although malaria is preventable and 
curable, it continues to be a major cause of 
morbidity and mortality. Plasmodium falciparum 
causes the most virulent form of malaria. The 
fight against malaria is complicated by the devel-
opment of parasite resistance to currently used 
treatment modalities.8 Thus, there is a con-
tinuous search for novel targets of anti-malarial 
therapy. The question of whether helicases can 
contribute to our fight against malaria is one 
step closer to being answered. in the January 
1, 2010 issue of Cell Cycle, Renu Tuteja from the 
international Centre for Genetic engineering 
and Biotechnology in india reports a bioinfor-
matics approach to identify members of several 
families of helicases in Plasmodium falciparum.9 
This study reveals the presence of members 
of the DeAD-box family of helicases that have 
no obvious human homologues. DeAD-box 
family is the largest family of RNA helicases 
which includes members involved in all aspects 
of RNA metabolism.10 Previous work from 
the same laboratory showed that targeting a 
DeAD-box RNA helicases can impair parasite 
growth.11 identification of novel agents that can 
target Plasmodium falciparum-specific helicases 
with the aim of disrupting their life cycle with 
little side effects on the human host would be a 
novel contribution to our fight against malaria.
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The NF-Y angle to the CCAAT ’s tale 
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Regulation of gene-specific transcription 
in eukaryotes is controlled by combinato-
rial arrangements and concerted functions 
of various short DNA sequence elements 
located around the transcription start site 
(TSS) of genes (promoters) as well as in 
distal regulatory regions (e.g., enhancers) 
that are recognized by diverse sequence-
specific DNA-binding proteins. The avail-
ability of completely sequenced genomes has 
promoted efforts to decipher by molecular 
and bioinformatics approaches the genome-
wide location and combinatorial assortment 
of some of these well-characterized tran-
scription regulatory sequences and cognate 
regulatory factors. in a previous issue of 
Cell Cycle, Dolfini et al. provide a new view 
of the type of promoters/genes controlled 
by the prototypical CCAAT box sequence 
and its associated ubiquitous NF-y regulator. 
These and similar studies are essential to 
our understanding of how specific genes are 
regulated but also will facilitate in silico iden-
tification of classes of genes and other non-
coding transcripts of unknown function that 
might be regulated via common pathways; 
this is particularly important given emerg-
ing evidence of widespread transcription 
throughout the genome, beyond the known/
annotated (RefSeq) genes. 1-3
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The first conserved DNA elements shown 
to control eukaryotic gene transcription were 
identified in the promoter regions of a few cel-
lular and viral protein-coding genes transcribed 
by mammalian RNA polymerase ii (Pol ii). 
These prototypical control elements include 
the notorious TATA and CCAAT boxes. The 
TATA box is a “core promoter element” located 
at -30 bp relative to the TSS (+1) that functions 
by recruiting the general/basal transcription 
initiation factor TFiiD and thereby nucleates 
the assembly of the rest of the basal transcrip-
tion machinery at the TSS; the CCAAT box 
is a “promoter-proximal” regulatory sequence 
that is found in either orientation upstream of 
the TATA box (in the -60/-200 bp region) and 
generally activates transcription.4,5 The factors 
that specifically recognize the CCAAT box were 
initially thought to be multiple and included C/
eBP, CTF/NF-i, NF-y and others. eventually the 
detailed characterization of the specific nucle-
otide sequence requirements for DNA binding 
by these different transcription regulators indi-
cated that NF-y is the major CCAAT-binding 
factor, which functionally recognizes not only 
the CCAAT pentanucleotide but also flanking 
nucleotides that perfectly match the statisti-
cal CCAAT consensus sequence.5,6 NF-y (also 
called CBF) is a heterotrimeric complex com-
posed of NF-yA, and the histone fold domain 
NFy-B and NF-yC subunits, which are all 
required for DNA binding; notably, the nuclear 
localization of NF-yC is cell cycle-regulated and 
dependent on dimer formation with NF-yB.7 
While NF-y is a “glutamine-rich” transcription 
activator that cooperates with neighboring 
promoter-bound factors and helps recruit the 
Pol ii machinery, it is also associated with gene 
repression and negative histone methyl-marks.8
early statistical and functional analyses sug-
gested that the TATA and CCAAT boxes are 
present and important in most protein-coding 
gene promoters.5 However, as many more 
promoters and 5' ends of mRNAs were accu-
rately characterized and genomes sequenced, 
it became apparent that only a minority of 
eukaryotic promoters have a TATA box - only 
~10-24% in humans.9,10 Now, Dolfini et al., 
in a previous issue of Cell Cycle, uncover a 
similar under-representation of the prototypi-
cal CCAAT box in human promoters by using 
a refined Position-Specific Frequency Matrix 
(PSFM) derived from experimentally validated 
NF-y/CCAAT sequences. They find that only 
~12% of all RefSeq protein-coding genes in 
the human genome contain “high confidence” 
NF-y/CCAAT boxes in their promoter region, 
significantly less than previous estimations using 
limited promoter datasets and earlier PSFMs.5,11 
importantly, the low frequency of NF-y/CCAAT 
boxes in promoters, is in agreement with recent 
“ChiP-on-chip” (chromatin immunoprecipita-
tion and hybridization to DNA microarrays) 
experiments, which indicated binding of NF-yA 
and NF-yB to, respectively, ~10% of 16,695 
promoters12 and ~22% of 907 promoters8 of 
human RefSeq genes. 
Dolfini et al. further define the CCAAT 
box-containing promoters/genes and verify that 
CCAAT boxes typically occur in several cop-
ies, in either orientation, and preferentially in 
the -80 bp promoter region of genes that are 
often involved in cell cycle and chromatin/
transcription, consistent with previous obser-
vations. More unexpectedly, however, CCAAT 
box-containing promoters generally lack a TATA 
box, have heterogeneous TSSs, and tend to be 
located within CpG islands. Thus, the traditional 
view of Pol ii promoters having both TATA and 
CCAAT boxes, based on the original charac-
terization of selected promoters, is very rare. 
These results also suggest a possible function of 
NF-y/CCAAT boxes in facilitating the recruit-
ment of the Pol ii machinery to TATA-less 
promoters, perhaps in a manner similar to GC 
boxes and cognate glutamine-rich activator SP1. 
Notably, Dolfini et al. uncover that CCAAT box-
containing promoters are enriched in sites for 
specific regulators such as SP1, e2F, CReB and 
USF/e-boxes, which are known to cooperate 
with NF-y, and sites for potentially new inter-
acting/cooperating regulators such as PAX, 
NFkB and eLK. interestingly, the authors further 
document that multiple NFy/CCAAT boxes are 
typically separated by one, or several, integral 
DNA helical turns, and observe “preferred” 
spacing between NF-y/CCAAT boxes and some 
of its cooperating regulators (SP1 and CReB), 
suggesting their global interactions. 
in conclusion, the studies by Dolfini et al. 
provide a new global view of the organization 
of human RefSeq genes/promoters regulated by 
the prototypical NF-y/CCAAT box and should 
help comparative studies of the structural 
and functional organization of all genomic loci 
bound by NF-y. indeed, it is intriguing that the 
vast majority (~80–90%) of NF-y binding sites 
analyzed by ChiP-on-chip on chromosomes 
20, 21 and 22 have been shown to reside 
outside of RefSeq promoters,8 suggesting that 
this might also be the case genome-wide. Do 
these most frequent distal NF-y/CCAAT sites 
also correspond to locations of promoters for 
novel mRNAs or non-coding RNAs,13 or do 
they represent regulatory enhancer/silencer 
or chromatin boundary regions?  Alternatively, 
could these sites reflect other non-transcription 
functions of NF-y/CCAAT? Clearly, the future 
promises more twists and turns to the NF-y/
CCAAT’s tale.
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Cycling mouse oocytes through meiosis 
Comment on: Miles DC, et al. Cell Cycle 2010; 9:408-18. 
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in eukaryotic species, cells divide by mitosis to 
clonally expand cell populations or by meiosis to 
generate genetically diverse gametes for sexual 
reproduction. However, despite its fundamental 
role in developmental biology, genetics and 
evolution, many aspects of the meiotic cell cycle 
are considerably less well understood than their 
mitotic counterparts. in mammalian species, 
the ability to divide by meiosis is restricted to 
germ cells, although the timing and regulation of 
meiosis differs between female and male germ 
cells. in females, proliferating germ cells initiate 
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the meiotic cell cycle en masse in the fetal 
ovary, pass through most of meiotic prophase, 
then arrest in the diplotene stage of meiotic 
prophase a few days after birth. in contrast, 
male germ cells become quiescent during late 
fetal development, and a continuous stream 
of proliferating male germ cells initiate and 
proceed through meiosis throughout adult life.1 
Although the differences in cell cycle behavior 
between male and female fetal germ cells have 
been known for some time, and are often used 
to distinguish whether fetal germ cells have 
embarked on male or female developmental 
programmes,2 little is known about how the cell 
cycle is regulated to drive this sexually dimor-
phic behavior. 
The study by Miles et al.3 in the previous 
issue of Cell Cycle uses transgenic mice that 
express GFP in the developing germ cells to 
analyze the expression of cell cycle regulators 
in purified female germ cells during meiotic pro-
phase. Miles et al. focus mainly on proteins such 
as cyclin B, and the DNA damage-associated 
kinases ATM and ATR that are known to be able 
to regulate progression through the G2-M tran-
sition in mitosis.3 The abundance of the active 
form of ATM, but not active ATR, in develop-
ing germ cells appears to be influenced by the 
sex-specific differences in cell cycle progression 
in fetal gonads.3 The high levels of active ATM 
and its downstream target Chk2 in oocytes 
during the early stages of meiotic prophase 
in oocytes presumably reflects the generation 
of meiotic DNA double-strand breaks during 
leptotene that stimulate meiotic recombination 
and chromosome synapsis during zygotene and 
pachytene. The ATM pathway may help to moni-
tor meiotic chromosome synapsis in oocytes 
by preventing cell cycle progression until chro-
mosome synapsis repairs all the meiotic DNA 
double-strand breaks in a manner analogous 
to ATM-mediated checkpoints preventing the 
mitotic G2-M transition in the presence of DNA 
double-strand breaks.4 
Perhaps one of the most salient findings of 
the study by Miles et al. is that expression of 
the three murine paralogs of cyclin B are dif-
ferentially regulated as oocytes pass through 
the first meiotic prophase to diplotene.3 in par-
ticular, expression of cyclin B3, which has been 
previously characterised as a meiosis-associated 
cyclin B paralog, is upregulated during the 
leptotene and zygotene stages of meiosis.3,5 
in contrast, cyclin B1 is downregulated during 
early meiotic prophase while cyclin B2 expres-
sion remains relatively unchanged.3 interestingly, 
human cyclin B3 is able to form a complex 
with Cdk2, although these complexes do not 
have strong kinase activity in vitro.5 it is not yet 
clear if the low kinase activity of cyclin B3-Cdk2 
complexes reflects the absence of correct bind-
ing partners, modifications, or meiosis-specific 
substrates in the in vitro assay, or whether the 
low kinase activity of cyclin B3-Cdk2 complexes 
might be important for the prolonged duration 
of prophase in meiotic cells. Regardless, it will 
be of interest to determine whether cyclin 
B3 mediates the distinct localization of Cdk2 
to meiotic chromosomes and/or the meiosis-
specific requirement for Cdk2 in progression 
through meiotic prophase.6,7 The expression 
of different cyclin B paralogs during mitosis 
and meiosis in female mouse germ cells is 
somewhat reminiscent of the expression of 
different cyclin A paralogs during mitotic and 
meiotic G2-M transitions in male mouse germ 
cells,8 and the preferential use of CLB1 or 
CLB2 cyclin B paralogs in meiosis and mitosis 
in budding yeast.9 indeed, understanding how 
the transcriptional networks in mitotic and 
meiotic germ cells generate the complemen-
tary expression patterns of paralogous genes 
such as cyclin B1 and cyclin B3 may shed 
some light on how some of the fundamental 
differences between mitosis and meiosis are 
brought about and how developing germ cells 
change their mode of cell division from mitosis 
to meiosis.
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Spindle assembly checkpoint inactivation: A new role for phosphatases 
Comment on: Visconti R, et al. Cell Cycle 2010; 9:564-9. 
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in eukaryotic cells, successful cell division 
requires the separation and distribution of the 
proper number of chromosomes into each 
daughter cell during each mitosis.  This process 
is accomplished by the bipolar mitotic spindle, 
which attaches microtubules to the kineto-
chores of paired mitotic chromosomes, facilitat-
ing their partition to each pole.  Failures in the 
attachment and function of the mitotic spindle 
can lead to aneuploidy and genome instability, 
which contributes to the development of cancer. 
To ensure the fidelity of chromosome segrega-
tion, an elaborate Spindle Assembly Checkpoint 
(SAC) monitors the attachment of the mitotic 
spindle to the kinetochores and the generation 
of bipolar tension on each chromosome pair.1 
Unattached kinetochores or tensionless kine-
tochores activate the SAC, which blocks cell 
division by inhibiting the Anaphase Promoting 
Complex/Cyclosome (APC/C), a ubiquitin ligase 
required for mitosis.  During each cell division 
cycle, the SAC inhibits the APC/C, and progres-
sion from metaphase into anaphase, until all 
the chromosomes are properly attached to 
the mitotic spindle, at which point the SAC is 
inactivated.1  
The main effector of the SAC is the Mitotic 
Checkpoint Complex, composed of MAD2, 
BUB3 and BUBR1, which binds and inhibits 
CDC20, the substrate adapter for the APC/C 
that is required for the induction of anaphase 
via the degradation of Securin.1  During each 
cell division cycle, the MCC binds CDC20, 
inhibiting the APC/C (and progression from 
metaphase into anaphase) until all the chro-
mosomes are properly attached to the mitotic 
spindle, at which point the SAC is inactivated. 
it has been reported that SAC inactivation 
might occur through APC/C-mediated ubiq-
uitination of CDC20, in a process indepen-
dent of proteasomal degradation that leads to 
the dissociation of MAD2 and BUBR1 from 
CDC20.2  However, more recent studies suggest 
that APC/C-mediated ubiquitination of CDC20 
leads to CDC20 degradation and sustains the 
SAC in response to mitotic spindle failures, 
suggesting that other mechanisms must control 
SAC inactivation.3,4  
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in previous issue of Cell Cycle, visconti et al. 
investigate other potential mechanisms control-
ling SAC inactivation and find evidence for the 
involvement of a protein phosphatase in licens-
ing SAC resolution and entry into anaphase. 
initially, their studies focused on the timing 
of SAC resolution, finding that the resolution 
of the SAC begins before the completion of 
the mitotic spindle and that the activation of 
the APC/C (in terms of Cyclin B degradation) 
lags behind the initial release of CDC20 from 
Mad2.  in combination with previous studies, 
these results suggested that an additional fac-
tor—possibly controlling phosphorylation—is 
required for inactivation of the SAC, and, indeed, 
CDC20 phosphorylation changes dramatically 
during SAC inactivation.5,6  Furthermore, the 
Mad2-CDC20 complex is stabilized in mitotic 
cells treated with proteasome inhibitors, but 
this complex can be dissociated by treatment 
with either cyclin-dependent kinase (CDK) 
or Aurora kinase inhibitors, which reduce 
CDC20 phosphorylation.  Because degradation 
of CDC20 by the proteasome is not required 
for resolution of the SAC, these results suggest 
that the degradation of an additional factor is 
required to reverse the CDC20 phosphoryla-
tions that contribute to Mad2 binding.3  Notably, 
Aurora A cannot phosphorylate CDC20, and 
proteolysis is unlikely to affect the activity of 
other kinases involved in the SAC.7  Therefore, 
it appears that SAC inactivation requires the 
activity of a phosphatase, whose inhibitor is 
subject to proteasomal degradation.  
The discovery of a role for a phosphatase 
and its inhibitor in SAC resolution is extremely 
important for our understanding of the cell 
division cycle, but the identity of these pro-
teins remains a mystery.  Previously, it was 
reported that the PP1 and PP2A phosphatases 
are activated by proteolysis to control mitotic 
exit;8 however, the present study shows that 
the phosphatase activity required for SAC 
resolution is insensitive to concentrations of 
okadaic acid that inhibit both PP1 and PP2A. 
Additionally, no reports have addressed the 
potential identity of the phosphatase inhibitor 
that must be degraded to allow SAC inactiva-
tion by phosphatase activity.  Nevertheless, 
visconti et al highlight an emerging role for 
protein phosphatases in controlling the SAC 
and the metaphase to anaphase transition, and 
further work is required to identity the key fac-
tors in this regulatory pathway.  
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New messages in the nuclear envelope 
Comment on: Malhas A, et al. Cell Cycle 2010; 9:531-9. 
William T. Dauer and Howard J. Worman; Email: dauer@umich.edu and hjw14@columbia.edu
The past decade has witnessed a growing appre-
ciation for the notion of the nuclear envelope 
(Ne) as an organelle that integrates and trans-
duces signals essential for metazoan develop-
ment and tissue homeostasis, broadening the 
conception of the Ne far beyond the traditional 
view of a fortress surrounding the nuclear 
contents.1 indeed, accumulating evidence that 
altered Ne-based signaling causes of a diverse 
array of human diseases has attracted the 
attention of a growing number of biomedical 
researchers, ranging from basic cell biologists to 
physician-scientists.1,2 One way that Ne-localized 
proteins can regulate signaling is by controlling 
the availability of transcription factors, either by 
regulating their entry and exit through nuclear 
pores or through sequestration at the inner 
nuclear membrane. The mechanisms whereby 
Ne proteins alter signaling are just beginning to 
be understood, however, so effects on transcrip-
tion factors likely represent only the tip of the 
iceberg of a range of Ne-localized modulatory 
mechanisms. 
in the previous issue of Cell Cycle, Malhas, 
Saunders and vaux provide evidence suggest-
ing that the Ne influences signaling via the 
regulation of miRNAs.3 They performed miRNA 
microarray profiling in mouse embryonic fibro-
blasts lacking full-length lamin B1, a major 
component of the nuclear lamina of all or most 
mammalian somatic cells. This screen identi-
fied 20 miRNAs with significantly increased 
or decreased expression. Subsequent experi-
ments, focused on the upregulated miRNA-31, 
identified candidate miRNA-31 targets, includ-
ing genes involved in cell cycle progression, 
such as Cdkn2a. Reducing miRNA-31 levels 
using a chemically modified nucleic acid inhibi-
tor in embryonic fibroblasts lacking lamin B1, 
which have greater proliferation rates than 
their wild type counterparts, decreased pro-
liferation. Re-expression of lamin B1 in lamin 
B1 null fibroblasts rescued the miRNA-31 and 
proliferation phenotypes. The authors also iden-
tified a miRNA-31 binding site in the 3'UTR of 
p16ink4a/p19Arf, potentially contributing to the 
cell cycle effects. 
This intriguing study is the first piece of 
evidence implicating the nuclear envelope in the 
regulation of specific miRNAs. However, future 
work will need to address several critical ques-
tions. For example, the phenotype of Lmnb1-/- 
mice is not easily explained by a generalized 
defect in cell proliferation. These mice die at 
birth, with relatively selective defects of lung 
and bone, and the Lmnb1-/- fibroblasts used by 
Malhas et al. have severely misshapen nuclei as 
well as other defects.4 miRNA profiling of sev-
eral tissues during the development of Lmnb1-/- 
mouse embryos might clarify the cell types and 
developmental windows particularly sensitive 
to miRNA-31 expression levels and uncover 
whether altered expression of other miRNAs 
account for the relatively specific phenotypes 
of bone and lung. Furthermore, as LMNB1 null 
humans have not been observed, the study of 
miRNAs in genetically modified mice or humans 
bearing a mutation associated with a human 
disease would provide more physiologically or 
“pathophsyiologically” relevant data. 
in this regard, the results of Malhas et al. 
intersect with exciting work done by ying-Hui 
Fu and colleagues. The Fu group has shown that 
a duplication of LMNB1 with increased lamin 
B1 expression causes adult-onset autosomal 
dominant leukodystrophy, a disorder character-
ized by widespread myelin loss in the central 
nervous system.5 They have further shown that 
miRNA-23 is a negative regulator of lamin B1 
expression and that this miRNA contributes to 
myelin maintenance by downregulating lamin 
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B1.6 Hence, lamin B1 may be at the center 
of a “signaling network” in which a miRNA 
regulates its own expression, which in turn 
regulates the expression of other miRNAs. 
The bidirectional interaction between lamin 
B1 and miRNAs adds to evidence implicating 
the nuclear envelope as a node that integrates 
and transduces a growing range of signals in 
development and disease.
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Hedgehog takes a new “RHOad” to angiogenesis 
Comment on: Chinchilla P, et al. Cell Cycle 2010; 9:570-9. 
Martin E. Fernandez-Zapico; Email: fernandezzapico.martin@mayo.edu
The Hedgehog proteins, highly conserved in 
vertebrates and invertebrates, are a family 
of secreted intercellular signaling molecules 
originally identified by genetic analysis of embry-
onic mutants of the Drosophila melanogaster.1,2 
Hedgehog ligands are critical in governing embry-
onic development and adult tissue homeostasis. 
They play an crucial role in the regulation in 
nearly all cellular processes including angiogene-
sis and neovascularization.1-3 Hedgehog proteins 
signal via two, multi-transmembrane proteins, 
named PATCHeD and SMOOTHeNeD.4,5 in 
this receptor complex, PATCHeD is the ligand-
binding subunit, while SMOOTHeNeD is the 
signaling component. Upon binding of HH to 
its receptor PATCHeD1, an inhibitory effect 
of PATCHeD on SMOOTHeNeD is released, 
allowing SMOOTHeNeD to trigger a signaling 
cascade that activates the GLi transcription 
factors (GLi 1, 2 and 3), which are essen-
tial effectors for Hedgehog-mediated cellular 
effects.5 in the absence of ligand, the Hedgehog 
signaling pathway is inactive. in this case, the 
transcription factors GLi undergo phosphoryla-
tion-dependent degradation. As a consequence, 
transcriptional activation of Hedgehog target 
genes is repressed. Pathway activation results 
in de-repression of SMOOTHeNeD, the central 
transducer for the signal, initiating a cascade 
that leads to the activation of GLi in the nucleus 
and regulation Hedgehog target genes.5,6  
in the study by Pilar Chinchilla and col-
leagues, the authors have identified a novel 
Hedgehog pathway independent of GLi tran-
scription factors.7 This pathway, activated by all 
three Hedgehog ligand (SONiC, iNDiAN and 
DeSeRT), promotes vessel formation in endo- 
thelial cells. Angiogenesis is a coordinated 
multistep process involving endothelial cell 
proliferation, migration and formation tubular 
structures. The authors have found that endo-
thelial cells do not respond to Hedgehog through 
the canonical pathway. None of the Hedgehog 
ligands were able to promote GLi transcrip-
tional activity in endothelial cells. However, all 
three ligands increased endothelial cell tubulo-
genesis in a SMOOTHeNeD-dependent manner. 
Hedgehog induces the typical elongated mor-
phology of activated endothelial cells. Analysis of 
the mechanism showed that Hedgehog requires 
an intact Gi protein function to form tubes. 
This Hedgehog stimulated SMOOTHeNeD-Gi 
axis activates through RAC1 the small GTPase 
RHOA and the formation of actin stress fibers 
in endothelial cells, a step that is key for tube 
organization. in addition to regulating the actin 
cytoskeleton, the Hedgehog ligands contrib-
ute to the angiogenic process by increasing 
endothelial cell survival through the inhibi-
tion of the pro-apoptotic effect of unligated 
PATCHeD receptor. interestingly, this effect is 
a SMOOTHeNeD-independent manner and 
Figure 1. Hedgehog proangiogenic signaling pathway. Schematic representation of this novel 
proangiogenic Hedgehog signaling cascade in endothelial cells. Hedgehog promotes tube forma-
tion through a SMOOTHeNeD-Gi-RAC1-RHOA pathway.  This cellular event is GLi independent 
and is accompanied by ligand dependent inhibition of PATCHeD pro-apoptotic functions in 
endothelial cells.
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involves the reduced CASPASe activation in 
response to pro-apoptotic stimuli (e.g., serum 
starvation). Thus, this study defines a novel 
non-canonical Hedgehog pathway and shifts the 
paradigm of Hedgehog signaling by supporting 
the existence of GLi-independent regulated 
cellular functions. Together these findings not 
only provide a novel insight into the biology of 
the Hedgehog cascade but could also serve as 
foundation for the development novel thera-
peutics and diagnostic approaches for diseases 
dependent on an active Hedgehog pathway. 
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A direct, non-canonical pathway for Hedgehog proteins in the endothelium 
Comment on: Chinchilla P, et al. Cell Cycle 2010; 9:570-9. 
Qingshi Zhao, Amanda Beck and Diego Fraidenraich; Email: fraidedi@umdnj.edu
The hedgehog (Hh) signaling pathway is impli-
cated in a broad spectrum of activities, rang-
ing from embryonic patterning to promoting 
angiogenesis in the adult.1,2 A common canonical 
paradigm has largely prevailed to explain the 
mode of action of Hh in such diverse types of 
processes. Hh ligands (Shh, ihh and Dhh) bind to 
and inhibit the inhibitory action of the Hh recep-
tor (Patched-1 or PTCH1) on Smoothened 
(SMO), the central transducer of the Hh path-
way. The rank order ofpotency is Shh >> ihh > 
Dhh.3 in the classical or canonical pathway, all 
signals carried by Hh proteins converge to a 
common family of transcription factors, termed 
Gli. inhibition of phosphorylation-dependent 
degradation of Gli-2 and -3 proteins by Hh leads 
to the widespread activation of the transcription 
of not only cell cycle, survival and pro-angiogenic 
factors, but also of various members of the Hh 
pathway cascade, like ptch1 and Gli1.3,4 The lat-
ter activation represents the hallmark of the 
classical response to Hh stimulation.
in the classical angiogenic paradigm, the 
inductive effect of Hh proteins on the formation 
of the new vasculature relies on the canonical 
action of Hh proteins on stromal fibroblasts. in 
the stroma, the Hh activity results in a robust 
Gli-dependent stimulation of veGF and other 
key angiogenic factors, whose action impacts the 
adjacent endothelium to promote angiogenesis.5 
Although there is emerging evidence  for the 
existence of non-canonical modes of action,6 
no data showing a direct effect of Hh on the 
endothelium has been documented as of yet.
in the previous issue of Cell Cycle, Chinchilla 
et al. elegantly show that a direct action of Hh 
proteins on endothelial cells (eCs) leads to 
organization of actin stress fibers and orches-
trates tubulogenesis through a non-canonical, 
Gli independent mechanism. Chinchilla et al. 
studied the effect of Hh proteins on human 
umbilical cord endothelial cells (HUveCs) or 
human cardiac microvascular endothelial cells 
(HMveCs). Unexpectedly, these eCs were 
responsive to Hh proteins, as they promoted 
tubulogenesis in 3D cultures. However,  ptch1 
or Gli1 were not transcribed, suggesting that the 
canonical pathway was not active. in contrast 
to stimulatory strength differences observed 
for Hh proteins (Shh>>ihh>Dhh) through 
the canonical mode of action, all Hh proteins 
promoted tubulogenesis with similar strength 
in the eCs. To dissect out the mechanism of 
action of Hh proteins on eCs, Chinchilla et al. 
employed chemical compounds, toxins, domi-
nant negative proteins and siRNA to inhibit/
neutralize specific points in the Hh pathway. 
Their findings indicate that the direct, non-
canonical induction of tubulogenesis appeared 
to be dependent on the activation of SMO 
and heterotrimeric G proteins. Activation of 
SMO led to the activation of the small GTPase 
RhoA, which induced a pronounced reorga-
nization of the actin cytoskeleton into stress 
fibers. This is the first time Hh isoforms have 
been shown to stimulate GTPase RhoA in 
endothelial cells via SMO and heterotrimeric 
Gi proteins.  Secondly, Chinchilla et al. went on 
to show that Hh proteins are also implicated 
in another novel, direct, non-canonical effect, 
this time independent of the action of SMO. 
This mechanism involves the inactivation of the 
apoptotic role of PTCH1 mediated by caspase 
activation. 
Taken all together, the work by Chinchilla 
et al. describes novel, direct, Gli-independent 
(SMO-dependent and SMO-independent) roles 
for Hh proteins on the endothelium. This work 
also sheds light on a potential link between 
RhoA and the Hh pathway. it would be intrigu-
ing to test if the RhoA-Hh link specifically takes 
place in the endothelium, or represents a more 
generalized process. it would also be interesting 
to determine how significant the contribution 
of this novel non-canonical pathway is in an in 
A novel Gli-independent, direct, non-canoni-
cal paradigm is depicted (red box).
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vivo setting, where canonical, paracrine, pro-
angiogenic effects also take place. Future work 
focused on the interaction and coordination of 
these two pathways may lead to new insights 
regarding angiogenic processes.  This study 
further opens the possibility for the explora-
tion of novel anti-angiogenic targets, whose 
inhibition may impinge on the action of Hh on 
the endothelium directly.  Overall, Chinchilla et 
al. offers a comprehensive study highlighting the 
biological relevance of non-canonical Hh signal-
ing in endothelial cells during angiogenic events. 
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p63 and canonical Wnt signaling 
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p63 as master regulator of epithelial 
stemness
ΔNp63α has been described as a “master 
gene” for maintenance of epithelial stemness 
in all stratified epithelia, at least in part by 
blocking apoptosis and differentiation. Thus, the 
human developmental ectrodactyly-ectodermal 
Dysplasia syndromes, marked by various muta-
tions in the p63 gene, as well as the phenotype 
of the global p63-null mice, put p63 in the 
center of regulating organogenesis of skin and 
skin adnexae as well as breast, prostate and 
urothelium. Moreover, ΔNp63α has also a role 
in an earlier phase of development by promot-
ing ectoderm formation and suppressing meso-
derm induction, as shown e.g. in mouse eS cells 
and in Xenopus laevis. 
ΔNp63α in tumor progression
An aberrant overexpression of ΔNp63 via gene 
amplification or increased protein translation is 
present in many epithelial carcinomas, such as 
squamous cell carcinoma and carcinomas of the 
bladder, breast and prostate. However, during 
tumor progression clinical studies repeatedly 
showed subsequent loss of ΔNp63α at least 
in some tumor types, which correlated with 
increased invasion and metastases and poorer 
prognosis for the patient.  For example, studies 
in bladder carcinoma showed that 50% of the 
cases exhibited aberrantly high levels of ΔNp63α 
protein. However, these were only non-invasive 
superficial carcinomas, while invasive tumors 
had lost p63 expression.1,2,3 Similar results were 
seen for carcinomas of the endometrium and 
esophagus. These results were paralleled in 
vitro in squamous cell carcinoma lines where 
p63 knockdown caused decreased cell adhesion 
and increased cell migration and was associated 
with the induction of an invasive transcrip-
tome.4 Thus, the effects of ΔNp63α in tumor 
formation appear stage dependent. 
The canonical Wnt signaling pathway 
in development 
The three major Wnt signaling pathways are 
involved in nearly every aspect of embryonic 
development and in adult tissue homeostasis. 
The canonical Wnt pathway governs specifica-
tion of cell identity, embryonal axis determina-
tion and regulation of cell proliferation and 
differentiation. it centers around beta-catenin, 
that upon stabilization binds to TCF/LeF tran-
scription factors and leads to the activation of 
multiple Wnt target genes involved in develop-
ment. in the default/inactive state, b-catenin is 
continuously degraded in the cytoplasm, and 
TCFs recruit corepressors (i.e., Groucho) to 
Wnt target genes. Conversely, upon Wnt ligand 
binding, b-catenin escapes its degradation fate, 
accumulates in the nucleus and replaces the 
TCF-bound co-repressors to occupy Wnt tar-
get genes. Once bound, b-catenin functions as 
a scaffold to recruit auxiliary machinery of co-
activators that are involved in chromatin remod-
eling to induce Wnt target gene expression. 
Specifically, the development of apical ecto-
dermal ridge (AeR), essential for limb develop-
ment in mammals, depends on the activity of 
the canonical Wnt pathway in the underlying 
mesenchyme.5 
The canonical Wnt signaling pathway 
in cancer
A dysregulation of the canonical Wnt signal-
ing in cancer is well established. Constitutively 
active Wnt signaling due to inappropriate stabi-
lization of b-catenin is the central theme here. 
This is achieved by loss-of-function mutations 
of components of the cytoplasmic destruction 
complex, such as the APC gene in the Familial 
Adenomatous Polyposis (FAP) syndrome lead-
ing to colon cancer, mutations in Axin1 or 
Axin2 in hepatocellular adenocarcinoma,or 
non-degradable, mutant b-catenin in tumors of 
colon, hair follicles and breast.  Moreover, aside 
from tumor initiation, b-catenin signaling is also 
very important during tumor progression since 
active Wnt signaling is heavily involved in cell 
migration and invasion and can cause epithelial-
to-mesenchymal transition (eMT).6,7
Partial overlap in expression and 
activity between p63 and components 
of canonic Wnt signaling
During development, specific tissues comprised 
of skin, hair follicles, mammary glands and limb 
buds (AeR) exhibit overlap in expression and 
function between ΔNp63α and components of 
Wnt signaling, suggesting a mechanistic interac-
tion. Some overlap can also be seen in tum-
origenesis and tumor invasion, as mentioned 
above. However, the paper by Drewelus et al. 
in the previous issue of Cell Cycle is only the 
second published report that directly addresses 
a putative crosstalk between ΔNp63α and the 
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b-catenin-Wnt signaling pathway. The first such 
connection came from a transient overexpres-
sion study by Patturajan et al. in 20028 reporting 
a positive synergism between the two. These 
authors concluded that ΔNp63 induces Wnt 
signaling by inhibiting GSK3b (another compo-
nent of the cytoplasmic b-catenin destruction 
complex) via binding to the subunit B56α of 
PP2A, thereby promoting nuclear accumulation 
of b-catenin. However, studies of human tumors 
did not find a correlation between overexpres-
sion of ΔNp63 and nuclear accumulation of 
b-catenin. in the second study reported here, 
Drewelus et al., using transient overexpression 
of ΔNp63α initially confirmed this cooperativ-
ity in the same cell system in vitro (HeK293). 
Moreover, inducible LeF-1 also cooperated 
with overexpressed ΔNp63α in vivo, generat-
ing secondary axis formation due to ectopic 
hyperactivation of Wnt signaling in Xenopus 
laevis embryos. Surprisingly though, downregula-
tion of endogenous levels of ΔNp63α in these 
authors' hands equally activated Wnt signal-
ing, as evidenced by a Wnt reporter gene and 
endogenous Wnt target genes, mainly Axin2. 
in addition, ΔNp63α was capable of physical 
interaction with multiple TCF/LeF family mem-
bers upon ectopic expression. The contact was 
mapped to the central DNA-binding domain 
of ΔNp63α and the HMG domain of LeF-1. 
Of note, neither levels nor phosphorylation 
status of b-catenin changed when Drewelus 
et al knocked down ΔNp63α, arguing for an 
additional interactive mechanism of Wnt signal-
ing activation taking place at the transcriptional 
level. While a limited study, what makes it inter-
esting is that the authors put forward an elegant 
simple model to plausibly explain the seeming 
paradox, i.e., how ΔNp63α overexpression 
and downregulation could both elicit the same 
net effect on Wnt signaling. By being a physical 
connector between TCF/LeF and putative co-
repressors of transcription, ΔNp63α—when 
overexpressed—would squelch the limiting 
concentrations of the co-repressors in a sepa-
rate complex, thereby artifactually derepressing 
TCF/LeF target genes. This would mimic the 
p63 knockdown situation. Similar explanations 
have been invoked previously for other tran-
scriptional regulators. For example, for Gal4 
in yeast and Fos/Jun or more recently e2F1 in 
mammalian cells, where ambiguous results were 
obtained after comparing overexpression with 
dominant negative blockade or knockout. As 
such, both overexpression of full length e2F1 
or e2F4 and their dominant-negative mutants 
resulted in displacement of the active Rb/e2F 
complexes from chromosomal sites and sub-
sequent target gene derepression imposed by 
associated corepressors, e.g. HDAC or BRG1/
BRM.9,10 Although it remains to be investigated, 
the model put forward that ΔNp63α antago-
nizes Wnt-induced transcription opens up the 
possibility that the limb bud phenotype due to 
AeR regression that is seen in p63KO mice is 
due to hyperactivation of Wnt signaling. This 
scenario would be consistent with the limb 
truncations seen with stabilized b-catenin (Hill 
2006).  A general repressor role of ΔNp63 
on the Wnt pathway, at first glance, seems 
difficult to reconcile with the observation of 
similar skin appendage abnormalities in both 
p63KO and LeF1 KO 11 or Tcf3/4 KO mice.12 
However, it was suggested that the role of 
Tcf3/4 in the epidermis consists at least par-
tially in a repressor function, and this would 
be in line with an auxiliary role of ΔNp63 
in TCF-mediated repression.12 Moreover, the 
antagonistic model is attractive for tumor pro-
gression since it could explain the association 
between loss of ΔNp63 expression and epithe-
lial mesenchymal transition (eMT) of invading 
carcinomas, a phenomenon in part dependent 
on Wnt signaling.
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New insights into KLF8-mediated transactivation 
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The Krüppel-like factor (KLF) family of tran-
scription factors control diverse processes, 
including regulation of the cell cycle, differentia-
tion, apoptosis, and tumorigenesis. KLF8 is no 
exception, and previous work has demonstrated 
a role for KLF8 in proliferation,1 Pi3K/Akt 
signaling,2 oncogenic transformation3 and cell 
invasion.4 As would be expected for a transcrip-
tion factor with such a wide variety of func-
tions, expression and activity of KLF8 is highly 
regulated, and in a manner that is only recently 
coming into focus. For example, activation of 
Focal Adhesion Kinase (FAK), a key effector of 
integrin signaling, results in increased expression 
of KLF8, at least partially through activation of 
the Pi3K/Akt signaling pathway and increased 
expression of Sp1.1,4 Post-translational modi-
fication of KLF8 via SUMOlyation at lysine 67 
attenuates the ability of KLF8 to both activate 
the Cyclin D1 gene and repress the Klf4 gene.5 
in addition, closely-related family members 
KLF1 and KLF3 activate and repress expression 
of KLF8, respectively.6
Less is known about how KLF8 modulates 
expression of its target genes. KLF8 has been 
shown to interact with the co-repressor CtBP, 
and mutation of the N-terminal sequence PvDLS 
to PvASLS markedly decreases the strength of 
this interaction in vitro.7 Similarly, KLF4 inter-
acts with CtBP8 and can both activate and 
repress target genes, depending on the cellular 
context and cofactors involved (see Fig. 1).9 
KLF4 recruits p300/CBP in order to activate 
expression of the iAP gene and promote acety-
lation of nearby histones.10 Thus, it is possible 
that KLF8 may act via a similar mechanism to 
transactivate the Cyclin D1 promoter.
indeed, in a recent issue of Cell Cycle 
(volume 9, issue 3), work from Urvalek, Wang, 
Lu and Zhao reveal that KLF8 interacts with 
the co-activators p300, CBP, and P/CAF.11 
Moreover, through detailed mutational analy-
sis, the authors identify Q118 and Q248 as 
key residues in mediating this interaction. The 
double point mutant KLF8-Q118N/Q248N is 
unable to interact with p300, CBP or P/CAF 
in an immunoprecipitation assay. Moreover, 
KLF8-Q118N/Q248N is significantly less able 
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to activate a Cyclin D1-Luciferase reporter 
construct, increase expression of the Cyclin D1 
protein or promote proliferation. 
p300, CBP and P/CAF all contain a HAT 
domain which catalyzes acetylation of nearby 
histones as well as other proteins. Consistent 
with this role, the authors demonstrate that 
overexpression of wild-type KLF8 results in 
increased histone acetylation on the Cyclin 
D1 promoter, whereas KLF8-Q118N/Q248N 
is markedly less able to increase acetylation. 
in p300-/-, CBP-/- and P/CAF-/- cells, KLF8 is 
significantly less able to activate a Cyclin D1 
reporter construct. Restoration of p300 or 
P/CAF expression at least partially restores 
activation of this reporter. interestingly, CBP has 
the opposite effect, and actually further inhibits 
the ability of KLF8 to activate the Cyclin D1 
reporter. in fact, even in wild-type MeF cells, 
overexpression of CBP blocks the ability of 
KLF8 to activate the reporter. Although it is 
unclear whether the effects of these coactiva-
tors on the Cyclin D1 reporter are exerted 
exclusively through KLF8 or through neigh-
boring transcription factors, these data clearly 
suggest differential roles for p300 and CBP in 
regulation of the Cyclin D1 gene.
These new data are exciting for several 
reasons. First, this is the first publication to 
demonstrate co-activators used by KLF8 for 
modulating transcription and promoting histone 
acetylation. KLF1, KLF4, KLF5, KLF6 and KLF13 
have all been shown to interact with p300, 
CBP, or P/CAF, suggesting that recruitment of 
these cofactors is part of a general mechanism 
for the function of transcription factors in the 
Krüppel-like factor family. Given that p300/CBP 
and P/CAF often acetylate the transcription 
factors they interact with, it will be interesting 
to test whether KLF8 is acetylated and what its 
function might be. Second, the authors identify 
two key residues in the KLF8 putative transac-
tivation domain that are critical for interactions 
with these cofactors. The double point mutant 
Q118N/Q248N will certainly be useful for fur-
ther studies in teasing out the precise molecular 
mechanisms of KLF8-mediated transcription. 
Finally, the authors demonstrate differential 
roles for p300 and CBP in modulating Cyclin 
D1 transcription, although the reason for this 
result is not entirely clear. it is worth noting that 
KLFs have distinct roles in cell proliferation and 
human cancers. KLF4 is a tumor suppressor in 
the Gi cancers and repress CyclinD1 expres-
sion, while KLF8 promotes transformation and 
activates CyclinD1 genes, suggesting that the 
roles of p300/CBP are highly context depen-
dent. it will be interesting to investigate whether 
CtBP plays any role in KLF8-mediated regula-
tion of the Cyclin D1 gene, and if p300 or CBP 
affects recruitment of CtBP or vice-versa. This 
new article from Urvalek and colleagues is quite 
interesting and is likely only the beginning of 
many subsequent publications on the molecular 
mechanisms of KLF8-mediated transcription.
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Figure 1. A general model for transcription mediated by members of the KLF family.  Krüppel-
like factors bind to their consensus CACCC motif on target genes and recruit the co-activators 
p300 or CBP.  These co-activators acetylate nearby histones and activate transcription.  The 
function of this complex can be modulated by histone deacetylases (HDACs) or the p300/CBP 
associated factor (P/CAF). Depending on the gene context, KLFs can also recruit co-repressors, 
such as CtBP, and repress transcription.  in addition, KLF family members often compete with 
each other or the closely related protein Sp1 for binding these CACCC consensus sequences, 
adding yet another level of regulation of KLF transcriptional activity. The role of p300 and CBP 
on KLFs acetylation and the functions of KLFs acetylation need to be further examined.  
KLF8 sets the pace for the cell cycle through interactions with p300 and PCAF 
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Krüppel-like factors (or KLFs) are a family of 
at least 17 transcription factors which share 
homology in their three C2-H2 zinc finger 
DNA binding domains. KLF8 has a well estab-
lished role in regulating cell cycle progres-
sion and oncogenic transformation.1,2 KLF8 can 
negatively regulate the globin3,4 and e-cadherin 
genes,5 and positively regulate genes such as 
cyclin D1 1. The mechanism for KLF8 negative 
regulation has been studied, and requires con-
tact with the C-terminal Binding Protein (CtBP) 
corepressor.3 The means by which KLF8 posi-
tively regulates genes was previously unknown. 
in the previous issue of Cell Cycle, Urvalek 
et al. demonstrate that KLF8 promotes histone 
acetylation at the cyclin D1 promoter, and 
that transactivation of the promoter by KLF8 
requires recruitment of the p300 or p300/CBP 
associated factor (PCAF) co-activators of the 
histone acetylase family.6 The Q118 and Q248 
amino acid residues are required for KLF8 to 
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transactivate the cyclin D1 promoter and for 
physical interactions between KLF8 and the 
co-activators.
KLF8 activates the cyclin D1 gene, promot-
ing cell cycle progression through the G1 phase.
1 
Other KLF factors also have demonstrated 
roles in controlling the cell cycle. For example, 
the cyclin D1 gene is a direct transcriptional 
target of KLF13 in the heart.7 eKLF (erythroid 
Krüppel-like factor or KLF1) was the first KLF 
family member to be described.8 Cells lacking 
eKLF/KLF1 have a defect in S-phase entry, likely 
due to reduced expression of e2f2 and e2f4, 
which are directly activated by eKLF.9,10 
The fact that KLF8 recruits p300 and PCAF 
increases the evidence for and number of KLF 
factors potentially using a common mechanism 
of transactivation. eKLF/KLF1, KLF2, KLF4, KLF5, 
KLF6, KLF8, KLF11 and KLF13 are now known 
to recruit co-activators of the histone acetylase 
family (see references in Urvalek et al. and 
ref. 11). it is not always clear in these examples 
whether acetylation of the KLF transcription 
factor, or acetylation of histones as is seen here 
for KLF8, is the primary mechanism for gene 
activation. KLF8 may be unique in that its trans-
activation domain directly interacts with p300/
PCAF, although the KLF domain required for 
such interactions is not well defined in all cases. 
it will be interesting to investigate in the future 
whether direct connections, such as those 
documented by Urvalek et al. for KLF8,6 exist 
between other KLFs, members of the histone 
acetylase family, and cell cycle progression.
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